Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Johnson & Johnson : California judge tosses $417 mln talc cancer verdict against J&J

share with twitter share with LinkedIn share with facebook
share via e-mail
10/21/2017 | 05:37am CEST

A California judge on Friday threw out a $417 million verdict against Johnson & Johnson in a lawsuit by a woman who claimed she developed ovarian cancer after using its talc-based products like Johnson's Baby Powder for feminine hygiene.

The ruling by Los Angeles Superior Court Judge Maren Nelson marked the latest setback facing women and family members who accuse J&J of not adequately warning consumers about the cancer risks of its talc-based products.

The decision followed a jury's decision in August to hit J&J with the largest verdict to date in the litigation, awarding California resident Eva Echeverria $70 million in compensatory damages and $347 million in punitive damages.

(c) All rights reserved The Jerusalem Post 1995 - 2017 Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
05:37a JOHNSON & JOHNSON : California judge tosses $417 mln talc cancer verdict against..
04:22a JOHNSON & JOHNSON : Judge tosses $417M award against Johnson & Johnson
01:47a JOHNSON & JOHNSON : Janssen receives two u.s. fda approvals for simponi aria® (g..
10/20 JOHNSON & JOHNSON : Ryan Tedder, Hamdi Ulukaya, Bulgari North America Honored at..
10/20 JOHNSON & JOHNSON : blames price cuts in India for poor show in knee-implant bus..
10/20 Healthcare looking in good shape
10/19 JOHNSON & JOHNSON : Janssen Submits New Drug Application to U.S. Food and Drug A..
10/19 JOHNSON & JOHNSON : The Fastest Growing Regions for Dermatological Drug Sales Ar..
10/19 JOHNSON & JOHNSON : Missouri court throws out $72M million verdict in Johnson & ..
10/19 JOHNSON & JOHNSON : Looking back on Black Monday, the stock market crash of 1987
More news
News from SeekingAlpha
10/20 FDA OKs expanded uses for J&J's Simponi Aria
10/20 The Best DGI Stocks For Young Investors - October 1-12, 2017
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 JOHNSON & JOHNSON : Create Your Own Dividends
10/20 I Love Earnings Season! Let's See How Abbott Laboratories, Johnson & Johnson ..
Financials ($)
Sales 2017 76 267 M
EBIT 2017 23 526 M
Net income 2017 15 953 M
Debt 2017 16 641 M
Yield 2017 2,36%
P/E ratio 2017 24,40
P/E ratio 2018 19,86
EV / Sales 2017 5,22x
EV / Sales 2018 4,82x
Capitalization 381 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 144 $
Spread / Average Target 1,3%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
AMGEN27.41%135 924